Breaking News

VGXI Joins Forces with Resilience to Advance Cell and Gene Therapy Manufacturing

The partnership aims to enhance Resilience's efficiency and overall capacity to meet the growing demand in the Cell and Gene Therapy sector.

Author Image

By: Charlie Sternberg

Associate Editor

VGXI Inc., a contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and National Resilience Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, have entered a strategic multi-year partnership in which VGXI will serve as a plasmid DNA manufacturer to support Resilience’s advanced therapy manufacturing programs.   VGXI’s abil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters